MOLECULAR MECHANISMS OF IMMUNE CORRECTING EFFECT OF CELL THERAPY UNDER DEVELOPMENT OF AUTOIMMUNE DISEASES

One of suppressor mechanisms controlling the tolerance during autoimmune diseases (AIDs) is the functioning of T-regulatory cells (CD4+CD25+). Rise in the content of Treg-cells in a recipient’s organism when treating AIDs is possible by triggering the molecular mechanisms with participation of cells producing indoleamine-2,3-dioxygenase (IDO) enzyme. Fetoplacental complex products (FPCP): placental cell suspension (PCS), fetal liver cells (FLCs) and fetal neuronal cells (FNCs) are the potential products of IDO. When using cryopreserved FPCP the change in metabolic processes of cells and proteins with immune modulating properties after freeze-thawing should be taken into account.

The research aim is comparative assessment of immune correcting effect of cryopreserved FPCP in respect of T-regulatory link of immunity at various AIDs.

The studies were performed in animals with the induction of adjuvant arthritis, experimental allergic encephalomyelitis and acute graft versus host reaction with following introduction of cryopreserved PCS, FLCs and FNCs, correspondingly. The number of CD4+CD25+ cells in spleen of the animals with AIDS prior to and after introduction of corresponding FPCP was examined with flow cytometer FACS Calibur. Content of ido gene transcripts in cryopreserved FPCP was examined by RT-PCR.

It has been shown that FPCP are capable of increasing the number of Treg-cells in a recipient’s body with AIDs, moreover the cryopreserved ones are doing in bigger extent. It is supposed that T-regulatory link of immunity of the animals with AIDs is stimulated according to IDO-dependent mechanism.